PRTA News and Press, Prothena Corporation plc From 06/02/22

DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management ...

Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and restricted cash position was $544.3 million Advanced PRX012, a potential best-in-class, subcutaneous treatment for Alzheimer’s disease, into a Phas...

DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2022...

PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer’s disease DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinic...

The electric vehicle sector fell sharply on Wednesday after spiking COVID cases in Shanghai raised broad concerns that the industry-wide supply chain disruption could extend even longer than anticipated. Chinese authorities extended a lockdown in Shanghai to cover all 26 million residents in ...

The following slide deck was published by Prothena Corporation plc in conjunction with this event. For further details see: Prothena Corporation (PRTA) Investor Presentation - Slideshow

Prothena (NASDAQ:PRTA) said the U.S. Food and Drug Administration cleared an investigational new drug (IND) application for its antibody drug candidate PRX012 to enter trial for treating Alzheimer’s disease (AD). The company said it has begun a phase 1 single ascending dose study ...

Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer’s disease DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investiga...

DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management...

Announcing preclinical data for its dual Aβ/tau vaccine targeted at Alzheimer’s disease, clinical-stage biotech Prothena Corporation (NASDAQ:PRTA) said on Wednesday that the company plans for an Investigational New Drug (IND) application for the candidate in 2023. In Addition, P...